Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
